文献速递鼻科

微创筛窦打孔窦切开术治疗无鼻息肉慢性鼻窦炎患者筛窦炎的安全性

Safe treatment of ethmoid sinusitis utilizing minimally invasive ethmoid punch sinusotomy in chronic rhinosinusitis without polyposis patients.
PubMed 文献 · Laryngoscope · 2017-02-14

本研究为单臂、机构审查委员会批准的观察性研究,纳入药物治疗失败且适合传统功能性内镜鼻窦手术的无鼻息肉慢性鼻窦炎(CRSsNP)伴活动性筛窦疾病患者,评估微创筛窦打孔窦切开术(EPS)的初步安全性。结果显示32个筛窦腔中29个(90.6%)保持通畅,所有通畅部位完全再黏膜化(29/29,100%),无黏液再循环(0/29,0%),筛窦LM评分1或2者全部改善至0(30/30,100%),SNOT-22评分平均降低33.1(术前49.6±7.5 vs 术后16.5±7.7,p<.0001)。作者认为EPS似乎是安全的微创手术,建立筛窦通气并可能改善有效鼻窦冲洗,适合开展临床试验评估其作用。

要点

  • 32个筛窦腔中29个(90.6%)EPS部位保持通畅,9个(28.1%)再狭窄,3个(9.3%)闭合。
  • 所有通畅EPS部位完全再黏膜化(29/29,100%),无黏液再循环(0/29,0%)或其他并发症。
  • 筛窦LM评分1或2者全部改善至0(30/30,100%);SNOT-22平均降低33.1(p<.0001)。

核心结论

  • 本可行性研究显示,EPS似乎是治疗药物治疗无效的CRSsNP患者筛窦炎的安全微创手术,可建立筛窦通气并可能改善有效鼻窦冲洗。
  • 作者认为开展临床试验评估EPS在该病管理中的潜在作用是合适的。

研究设计与样本

  • 单臂、机构审查委员会批准的观察性研究。
  • 研究对象为药物治疗失败、适合标准传统功能性内镜鼻窦手术并获提供EPS选项的CRSsNP患者。
  • 共32/40个可能筛窦腔(前组17/20,后组15/20)接受EPS。

主要发现

  • 29/32个EPS部位保持通畅(90.6%),9个(28.1%)显示再狭窄证据,3个(9.3%)闭合。
  • 所有通畅EPS部位完全再黏膜化(29/29,100%),无黏液再循环(0/29,0%)或继发于愈合或器械使用的其他并发症。
  • 术前LM评分为1或2的筛窦腔全部改善至0(30/30,100%)。
  • SNOT-22评分显著改善,平均降低33.1(术前49.6±7.5 vs 术后16.5±7.7,p<.0001)。

临床怎么用

  • 作者认为EPS似乎是治疗药物治疗无效的CRSsNP患者筛窦炎的安全微创手术,可建立筛窦通气并可能改善有效鼻窦冲洗。
  • 作者认为开展临床试验评估EPS在该病管理中的潜在作用是合适的。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES/HYPOTHESIS: Current rhinologic practice is devoid of minimally invasive procedures dedicated to the treatment of ethmoid sinusitis to improve ventilation and topical drug delivery. We have recently described a handheld spiral punch to create minimally invasive ethmoid punch sinusotomy (EPS) sites into the ethmoid bulla and basal lamella, which significantly increased irrigant access to the ethmoid sinuses in cadaver models. Here, we conducted a clinical feasibility study to determine the initial safety evaluation of EPS in chronic rhinosinusitis without polyposis (CRSsNP) patients with active ethmoid disease. STUDY DESIGN: Single-arm, institutional review board-approved observational study. METHODS: This study was performed in CRSsNP patients who failed medical management; were candidates for standard, traditional functional endoscopic sinus surgery; and were offered the option of EPS. EPS characteristics (patency, remucosalization) and complications (closure, mucus recirculation) were collected. Alterations in radiographic disease and symptoms after EPS were determined by Lund Mackay (LM) scoring and 22-item Sinonasal Outcome Test (SNOT-22) scoring, which was collected up to 6 months post-procedure. RESULTS: Thirty-two of 40 possible ethmoid compartments (17 of 20 anterior, 15 of 20 posterior) underwent EPS. Twenty-nine of 32 EPS sites remained patent (n = 29, 90.6%), with a minority displaying evidence of restenosis (n = 9, 28.1%) or closure (n = 3, 9.3%). All patent EPS sites had complete remucosalization (n = 29, 100%) with no evidence of mucus recirculation (n = 0, 0%) or other complications secondary to healing or device use. Ethmoid sinus cavities with a pre-EPS LM score of 1 or 2 universally improved to an LM score of 0 following EPS (n = 30 of 30, 100%). SNOT-22 scores significantly improved, with a mean reduction of 33.1 (49.6 ± 7.5 pre-EPS vs 16.5 ± 7.7 post-EPS, p < .0001). CONCLUSIONS: This feasibility study demonstrates that EPS appears to be a safe, minimally invasive procedure to treat ethmoid sinusitis in CRSsNP patients unresponsive to medical therapy that establishes ethmoid ventilation, and likely improves effective sinus irrigation. Conducting a clinical trial would be appropriate in assessing a potential role for EPS in the management of this condition. LEVEL OF EVIDENCE: 4. Laryngoscope, 127:1268-1275, 2017.

来源:Laryngoscope,查看原文。版权归原作者所有。

引用

  1. Velasquez N, Thamboo A, Abuzeid WM, et al. Safe treatment of ethmoid sinusitis utilizing minimally invasive ethmoid punch sinusotomy in chronic rhinosinusitis without polyposis patients. Laryngoscope. 2017. PMID: 28194802. doi:10.1002/lary.26493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。